Short Interest in Evolus, Inc. (NASDAQ:EOLS) Declines By 6.6%

Evolus, Inc. (NASDAQ:EOLS) was the target of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 4,650,000 shares, a decrease of 6.6% from the March 15th total of 4,980,000 shares. Based on an average trading volume of 657,700 shares, the days-to-cover ratio is presently 7.1 days. Approximately 9.8% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on EOLS shares. Barclays upgraded shares of Evolus from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $10.00 to $16.00 in a research report on Monday, January 29th. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research note on Friday, March 1st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Evolus in a research report on Wednesday, April 10th.

Insider Activity

In related news, insider Rui Avelar sold 27,603 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total transaction of $384,233.76. Following the transaction, the insider now owns 372,288 shares of the company’s stock, valued at $5,182,248.96. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, CFO Sandra Beaver sold 5,672 shares of Evolus stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $13.92, for a total value of $78,954.24. Following the sale, the chief financial officer now owns 154,201 shares of the company’s stock, valued at $2,146,477.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Rui Avelar sold 27,603 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $13.92, for a total transaction of $384,233.76. Following the completion of the sale, the insider now owns 372,288 shares of the company’s stock, valued at approximately $5,182,248.96. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 60,969 shares of company stock valued at $831,005. 5.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Evolus

Several institutional investors and hedge funds have recently made changes to their positions in EOLS. Point72 Hong Kong Ltd raised its holdings in Evolus by 979.7% in the first quarter. Point72 Hong Kong Ltd now owns 2,343 shares of the company’s stock valued at $26,000 after acquiring an additional 2,126 shares in the last quarter. Metropolitan Life Insurance Co NY acquired a new stake in shares of Evolus in the 1st quarter valued at about $26,000. Point72 Middle East FZE bought a new position in shares of Evolus during the fourth quarter worth about $39,000. Tower Research Capital LLC TRC grew its stake in Evolus by 453.6% in the third quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $51,000 after purchasing an additional 5,221 shares in the last quarter. Finally, Ensign Peak Advisors Inc bought a new stake in Evolus in the third quarter valued at about $54,000. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Trading Down 3.4 %

Shares of EOLS stock opened at $11.64 on Thursday. Evolus has a twelve month low of $7.07 and a twelve month high of $15.43. The company has a market capitalization of $674.42 million, a PE ratio of -10.68 and a beta of 1.45. The firm has a fifty day simple moving average of $13.67 and a 200-day simple moving average of $11.13.

Evolus (NASDAQ:EOLS) last announced its earnings results on Thursday, March 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). The firm had revenue of $61.00 million during the quarter, compared to analyst estimates of $61.14 million. Equities research analysts predict that Evolus will post -0.51 EPS for the current year.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.